Chiesi Group to Acquire KalVista Pharmaceuticals for $1.9 Billion

Chiesi Group has announced its intent to purchase KalVista Pharmaceuticals for approximately $1.9 billion, or $27 per share. This acquisition aims to enhance Chiesi's rare immunology portfolio, specifically by adding EKTERLY®, a treatment for hereditary angioedema. Both companies' boards have approved the transaction, which is expected to finalize in the third quarter of 2026.